Safety and Outcomes of Hypofractionated Radiotherapy After Surgery for Endometrial Cancer
Led by McGill University Health Centre/Research Institute of the McGill University Health Centre · Updated on 2026-10-13
50
Participants Needed
1
Research Sites
260 weeks
Total Duration
AI-Summary
What This Trial Is About
Endometrial cancer is a common malignancy affecting women, and this research aims to evaluate the safety and effectiveness of a special radiation treatment called hypofractionated radiotherapy in women with this cancer. This approach involves delivering fewer radiation treatments at higher doses, which may reduce overall treatment time and impact on patients. The study focuses on understanding both short-term and long-term side effects, as well as the treatments ability to prevent cancer recurrence and its effects on patients overall health and quality of life.
Participants will receive whole pelvic radiotherapy in five sessions given every other day, totaling a dose of 28.5 Gy, with an option for an additional vaginal brachytherapy dose for some patients. This treatment is delivered using advanced RapidArc technology. The study follows patients over time, assessing the outcomes of this hypofractionated radiation approach after surgery that removes the uterus and ovaries and includes lymph node evaluation.
During the study, participants will attend 15 clinic visits over five years, during which they will complete nine questionnaires about their health and quality of life. Standard blood tests and imaging will be performed regularly to monitor cancer status and treatment effects. Researchers will carefully track side effects and overall health to assess the safety and effectiveness of this radiation method in the long term.
CONDITIONS
Brief Title
Safety, Efficacy and Quality of Life After Adjuvant Hypofractionated Radiotherapy for Endometrial Cancer
Research Team
J
Joanne Alfieri, MD
M
Marianna Perna, CCRP
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match. Sign up to get personalized trial recommendations delivered to your inbox.
McGill University Health Centre/Research Institute of the McGill University Health Centre
Lead Sponsor
Who Can Participate
Age: 18Years +
FEMALE
Eligibility Criteria
You may qualify if you...
Patients 18 years of age or older with ECOG performance status 0-2
Newly diagnosed endometrial carcinoma including endometrioid, serous, clear cell, carcinosarcoma, and dedifferentiated tumors
FIGO 2009 stage I to IIIC1
Previous total hysterectomy with bilateral salpingo-oophorectomy and sentinel lymph node biopsy or pelvic nodal dissection with no residual disease
Indication for adjuvant pelvic radiotherapy as determined by radiation oncology physician
You will not qualify if you...
ECOG performance status 3 or higher
Para-aortic nodal disease
Non-standard surgery or residual disease after surgery
Need for radiotherapy field larger than whole pelvis
Active inflammatory bowel disease
Active scleroderma
Previous cancer in the last 5 years except non-melanoma skin cancer
Contraindication to CT contrast
Inability to meet dose constraints or reproduce simulation positioning for treatment
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Treatment
Duration - Approximately 2 weeks
Participants receive whole pelvic hypofractionated radiotherapy in five sessions on alternate days, with possible vaginal brachytherapy boost if needed.
5 treatment visits
Follow-up
Duration - 60 months
Participants attend regular clinic visits over 60 months to complete questionnaires and undergo blood tests and imaging to monitor health, side effects, and cancer status.
15 visits with 9 questionnaires
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SEQUENTIAL
Primary Purpose
TREATMENT
Number of Arms
1
Similar Trials
Safety and Dosimetry Study of 177Lu-RAD204 Targeting PD-L1 in Patients With Selected Metastatic Solid Tumors
Study of 177LuBetaBart Monoclonal Antibody for Safety and Early Effects in Adults With Advanced Solid Tumors
Evaluating 18F-T2 PETCT Imaging for Detecting Tumors with High CAIX Levels in Adults
Study of Using 3D-Printed Custom Devices for High-Dose Radiation Treatment in Gynaecological Cancer
Phase III Trial Comparing BNT323 Versus Chemotherapy for HER2-Positive Recurrent Endometrial Cancer
Study on Cervical and Endometrial Cancer in Women Aged 20 to 75
Open-Label Phase 1 Trial Evaluating Safety and Activity of HH160 Alone or With Other Cancer Treatments in Adults With Advanced or Metastatic Solid Tumors
Study of CTIM-76, a Claudin-6 Directed Bispecific Antibody, in Adults With Platinum-Resistant Ovarian Cancer and Advanced Solid Tumors
Phase 1 Open-label Study of LNCB74, a B7-H4 Targeted Antibody Drug Conjugate, Given Intravenously in Advanced Solid Tumors to Determine Safety and Recommended Dose
Phase 1a1b Study of NRM-823 Alone and With Immune Checkpoint Inhibitor in Advanced or Metastatic Refractory Solid Tumors
Have more questions? Get in touch with our team for quick support
Published Research Related To This Trial
Phase 1/2 trial evaluating the effectiveness and safety of dose-adapted Hypofractionated pelvic radiotherapy for Advanced Cervical cancers INeligible for ChemoTherapy (HYACINCT).
Early Tolerance Outcomes of Stereotactic Hypofractionated Accelerated Radiation Therapy Concomitant with Pelvic Node Irradiation in High-risk Prostate Cancer.
Attapol Pinitpatcharalert, Laura Happersett, Marisa Kollmeier...
Long-term results of a randomized trial comparing preoperative short-course radiotherapy with preoperative conventionally fractionated chemoradiation for rectal cancer.
Hypofractionated breast radiotherapy for 1 week versus 3 weeks (FAST-Forward): 5-year efficacy and late normal tissue effects results from a multicentre, non-inferiority, randomised, phase 3 trial.
Adrian Murray Brunt, Joanne S Haviland, Duncan A Wheatley...
The UK Standardisation of Breast Radiotherapy (START) trials of radiotherapy hypofractionation for treatment of early breast cancer: 10-year follow-up results of two randomised controlled trials.
A Prospective Study of Stereotactic Body Radiotherapy (SBRT) with Concomitant Whole-Pelvic Radiotherapy (WPRT) for High-Risk Localized Prostate Cancer Patients Using 1.5 Tesla Magnetic Resonance Guidance: The Preliminary Clinical Outcome.